Search

KR-20260068058-A - Composition and method for controlling melanin production

KR20260068058AKR 20260068058 AKR20260068058 AKR 20260068058AKR-20260068058-A

Abstract

Zinc di-(dibutyryl ricinate), topical compositions containing the same, and their use in skin whitening/brightening/even skin tone applications.

Inventors

  • 차우두리 라탄 케이.

Assignees

  • 시테온 리미티드

Dates

Publication Date
20260513
Application Date
20240717
Priority Date
20230718

Claims (20)

  1. Compound zinc di-(di-n-butyryl ricinate) shown in Structure 1: Structure 1.
  2. Compound zinc di-(di-isobutyryl ricinate) shown in Structure 2: Structure 2.
  3. A composition comprising a zinc dibutyryl ricinate component selected from zinc di-(di-n-butyryl ricinate), zinc di-(di-isobutyryl ricinate) and mixtures thereof, (ii) optionally a skin whitening agent other than (i), and (iii) a dermatologically acceptable carrier.
  4. In paragraph 3, the zinc dibutyryl ricinate component is a composition in which zinc di-(di-n-butyryl ricinate).
  5. In paragraph 3, the zinc dibutyryl ricinate component is a composition in which zinc di-(di-isobutyryl ricinate).
  6. A composition in which the skin whitening agent (ii) is present in any one of claims 3 to 5.
  7. In claim 6, the skin whitening agent is a composition selected from hexylresorcinol, bakuchiol, acetyl gingerone, and a combination of two or more of these.
  8. A composition according to any one of claims 3 to 7, wherein the zinc dibutyryl ricinate component is present in an amount of about 0.05 to about 10 weight% relative to the total weight of the composition, and the skin whitening agent (ii), when present, is present in an amount of about 0.05 to about 20 weight% relative to the total weight of the composition, and the weight ratio of the zinc dibutyryl ricinate component to the skin whitening agent (ii) is about 10:1 to about 1:10.
  9. A composition according to any one of claims 3 to 7, wherein the zinc dibutyryl ricinate component is present in an amount of about 0.1 to about 10 weight% relative to the total weight of the composition, and the skin whitening agent (ii), when present, is present in an amount of about 0.1 to about 10 weight% relative to the total weight of the composition, and the weight ratio of the zinc dibutyryl ricinate component to the skin whitening agent (ii) is about 5:1 to about 1:5.
  10. A composition according to any one of paragraphs 3 to 9, further comprising one or more skin-protective or therapeutic ingredients in an effective amount.
  11. In claim 10, one or more skin protective or therapeutic ingredients are a composition selected from the group consisting of UV blocking active ingredients, antioxidants, vitamins, anti-inflammatory agents, moisturizers, emollients, humectants, and mixtures thereof.
  12. In claim 10, one or more skin protective or therapeutic ingredients are a composition selected from bakuchiol, isosorbide dicaprylate, Terminalia chebula fruit extract, ethyl linoleate, isosorbide dilinoleate, isosorbide diunflower ate, and mixtures thereof.
  13. A composition in any one of paragraphs 3 to 12, wherein the dermatological carrier is a formulation product selected from cosmetics, sunscreens, moisturizers, skin serums, anti-aging compositions, acne treatments, general skin care products, regenerative products, topical medicines, or sunburn treatments, or a base composition for manufacturing a formulation product.
  14. A composition according to any one of claims 3 to 13, further comprising one or more dermatologically acceptable amphoteric surfactants, ethanol, or mixtures thereof.
  15. A method for whitening/brightening/creating an even skin tone, maintaining skin color and an even tone, and preventing skin discoloration, comprising applying a composition containing an effective amount of zinc dibutyryl ricinate selected from zinc di-(di-n-butyryl ricinate), zinc di-(di-isobutyryl ricinate), and mixtures thereof to a skin area where the desired effect is to be achieved.
  16. In claim 15, the composition comprises (i) a zinc dibutyryl ricinate component, (ii) optionally a skin whitening agent other than (i), and (iii) a dermatologically acceptable carrier.
  17. In paragraph 15 or 16, the zinc dibutyryl ricinate component is zinc di-(di-n-butyryl ricinate).
  18. A method according to any one of claims 15 to 17, wherein a skin whitening agent (ii) is present and selected from hexylresorcinol, acetylgingerone and combinations thereof.
  19. A method according to any one of claims 15 to 18, wherein the zinc dibutyryl ricinate component is present in an amount of about 0.05 to about 10 weight% relative to the total weight of the composition, and the skin whitening agent (ii) is present in an amount of about 0.05 to about 20 weight% relative to the total weight of the composition when present, and the weight ratio of the zinc dibutyryl ricinate component to the skin whitening agent (ii) is about 10:1 to about 1:10.
  20. A method of applying a composition to the whole or substantially whole area of the skin to achieve overall skin whitening/brightening/uniform skin tone in any one of claims 15 to 19.

Description

Composition and method for controlling melanin production Related applications This application claims priority to U.S. Provisional Patent Application No. 63/527,483, filed July 18, 2023, (“Novel amino acid-based histone deacetylase modulator for skin treatment”) and U.S. Provisional Patent Application No. 63/621,598, filed January 17, 2024, (“Composition and method for regulating melanin production”), the contents of which are incorporated herein by reference. Technology field The present invention relates to a novel compound, also known as zinc di-(dibutyryl lysine) (INCI name: zinc dibutyroylicinate) or bis(N2, N6-dibutyryl-lysine) zinc salt (2:1), and its uses, which are used to prevent, alleviate, and/or reverse the occurrence of hyperpigmented spots, age spots, melasma, freckles, melanin pigmentation, etc. caused by sunlight, laser treatment, acne, and scars, as well as to whiten/brighten/create a uniform skin tone. Human skin color varies greatly worldwide. Some Africans, Australians, and Asian Indians have very dark brown skin, while some Northwestern Europeans have pinkish-yellow skin. No one truly has black, white, red, or yellow skin. While these terms are commonly used, they do not reflect biological reality. Human skin color is determined by a complex series of cellular processes occurring within a group of cells known as melanocytes located beneath the epidermis. These processes result in the synthesis and transport of a pigment called melanin, which, in addition to determining skin color and tone, serves as a key physiological defense mechanism protecting the skin from sun-induced damage such as sunburn, photoaging, and photocarcinogenesis. The mechanism by which melanin is produced is called melanogenesis. The melanin produced in this way accumulates or is deposited in melanosomes, which are vesicles located within melanocytes. Subsequently, it moves from melanocytes to keratinocytes, is absorbed, and transported to the skin surface. Skin color is primarily regulated by the amount and type of melanin synthesized in epidermal melanocytes. However, additional and equally contributing factors include (a) the efficiency of transferring melanosomes—i.e., melanin—from melanocytes to adjacent keratinocytes, and (b) the process by which the transferred melanosomes are subsequently distributed and broken down by recipient keratinocytes. Environmental factors can also significantly influence skin color. For example, exposure to sunlight greatly increases the amount and rate of melanin production, often resulting in the skin becoming darker or "tanned." Conversely, exposure to other factors, such as substances that interfere with melanin production and/or melanin transfer, may reduce the amount of melanin produced or the speed and efficiency of transfer, thereby causing skin lightening. In melanocytes, microphthalmia-associated transcription factor (MITF) plays a critical role known as the 'major transcription regulator' of the melanocyte lineage ( Hemesath et al, microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family.Genes Dev 1994; 8: 2770-2780; Nguyen and Fisher, MITF and UV responses in skin: from pigmentation to addiction, Pigment Cell Melanoma Res, 32(2): 224-236, 2019 ). MITF has been identified as the most important transcription regulator that controls numerous signals involved in gene expression related to melanin production. MITF regulates the expression of genes that play essential roles in cell differentiation, proliferation, and survival. MITF plays a critical role in melanocyte development by regulating the expression of tyrosinase (TYR) and tyrosinase-associated proteins 1 (TRP1) and 2 (TRP2). MITF not only regulates the expression of numerous pigment genes to promote melanocyte differentiation, but also regulates the expression of genes essential for maintaining cellular homeostasis, such as those encoding proteins involved in apoptosis (e.g., BCL2 ) and the cell cycle (e.g., CDK2 ). Interestingly, many molecular pathways critical to pigment cell development are also involved in melanoma formation; therefore, mechanisms regulating pigment cell development can provide valuable insights into the malignant transformation of cells ( Hsiao and Fisher, The roles of Microphthalmia Transcription Factor and pigmentation in melanoma, Arch Biochem Biophys, 563, 28-34, 2014). As mentioned earlier, melanocytes produce melanin pigment and transfer it to keratinocytes, where melanin plays roles such as protecting the skin from ultraviolet radiation. Tyrosinase oxidizes tyrosine to L-dopa, initiating melanin production, which is the melanin biosynthetic pathway. MITF stimulates melanin production by activating the transcription of TYR and other pigment genes, including TRP1, TRP2 (DCT), PMEL, and MLANA ( Yasumoto, et al, Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene,